Accelerating Access to Critical Therapies for ALS Act
Bill journey · stage 2 of 5
Under committee review
What it doesSummary introduced in house (Oct 23, 2020)
Accelerating Access to Critical Therapies for ALS Act
This bill establishes grant programs to address neurodegenerative diseases, such as amyotrophic lateral sclerosis (also known as ALS or Lou Gehrig's disease), and contains other related provisions.
The Department of Health and Human Services (HHS) shall award grants to eligible entities to support research on and facilitate access to investigational drugs that diagnose or treat ALS. The Food and Drug Administration shall award grants to public and private entities to cover the costs of research and development of drugs that diagnose or treat ALS and other severely debilitating neurodegenerative diseases.
HHS shall also establish the Collaborative for Neurodegenerative Diseases, which shall support the development and regulatory approval of drugs that address ALS and other rare neurodegenerative diseases.
What just happenedOct 23, 2020
Referred to the House Committee on Energy and Commerce.
Who’s behind it
- Introduced in HouseOct 23, 2020
- Oct 23, 2020IntroReferralH11100
Referred to the House Committee on Energy and Commerce.
Energy and Commerce Committee - Oct 23, 2020IntroReferralIntro-H
Introduced in House
- Oct 23, 2020IntroReferral1000
Introduced in House